Table 1.
Clinical, hemodynamic, and laboratory data of patients recruited.
| Group 0 (standard therapy) (n = 58) |
Group 1 (tailored therapy) (n = 58) |
P value | |
|---|---|---|---|
| Male sex n (%) | 41 (71) | 38 (65) | 0.51 |
| Age* | 59 ± 7 | 61 ± 11 | 0.33 |
| BMI* | 27 ± 2 | 27 ± 5 | 0.77 |
| LVEF* | 46 ± 4 | 45 ± 5 | 0.64 |
| Current smoking, n (%) | 16 (28) | 16 (28) | 0.98 |
| LDL-Cholesterol* | 129 ± 34 | 135 ± 14 | 0.51 |
| Diabetes mellitus, n (%) | 16 (28) | 18 (31) | 0.41 |
| Hypertension, n (%) | 31 (54) | 35 (61) | 0.27 |
| Time to balloon, min* | 112 ± 18 | 102 ± 18 | 0.42 |
| Pre-PCI Abciximab, n (%) | 6 (10) | 5 (8) | 0.59 |
| Pre-PCI TIMI flow* | 0.4 ± 0.2 | 0.5 ± 0.2 | 0.89 |
| Post-PCI TIMI flow* | 2.8 ± 0.3 | 2.9 ± 0.3 | 0.71 |
| Number of diseased vessels* | 1.6 ± 0.3 | 1.4 ± 0.4 | 0.86 |
| Number of treated vessels* | 1.2 ± 0.2 | 1.1 ± 0.2 | 0.78 |
| Number of balloon/patient | 2.8 ± 0.4 | 2.6 ± 0.4 | 0.43 |
| Number of stents/patient* | 1.4 ± 0.3 | 1.3 ± 0.3 | 0.65 |
| Number of DES, n (%) | 29 (50) | 27 (48) | 0.63 |
| Stent length/patient, mm* | 28 ± 7 | 26 ± 7 | 0.73 |
| Time between PCI and PFA-100, h* | 120 ± 10 | 120 ± 8 | 0.86 |
| Hemoglobin, g/dL* | 13.8 ± 3.2 | 13.1 ± 3.4 | 0.84 |
| Leukocytes, g/L* | 7.8 ± 1.8 | 7.2 ± 1.6 | 0.67 |
| Platelets, 103 g/L* | 220 ± 53 | 241 ± 53 | 0.51 |
| High sensitivity RCP, mg/dL | 1.36 ± 0.8 | 1.22 ± 1.1 | 0.64 |
| Fibrinogen, g/L* | 3.2 ± 1.0 | 3.5 ± 0.9 | 0.18 |
| Creatinine, mg/dL* | 1.2 ± 0.3 | 1.1 ± 0.3 | 0.64 |
| Cytochrome P450 metabolized drugs, n (%)** | 58 (100) | 57 (98) | 0.97 |
BMI: body mass index; CAD: coronary artery disease; TIMI: thrombolysis in myocardial infarction; DES: drug eluting stents; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention; PFA: platelet function analyzer. *Mean ± standard deviation; **calcium channels antagonists, high dose statins.